Therapeutic ReviewsDo Tumor Necrosis Factor (TNF) Inhibitors Improve the Glycemic Control in Patients with Rheumatoid Arthritis and Concomitant Diabetes Mellitus?Danve, Abhijeet S. MD1,*; Kulkarni, Supriya MD2Author Information Divisions of 1Rheumatology and 2Diabetes, Endocrinology and Metabolism, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE. *Address for correspondence: 11322 Franklin Plaza No. 915, Omaha, NE 68154. E-mail: [email protected] The authors have no conflicts of interest to declare. A. S. Danve and S. Kulkarni have participated equally in the research work, have met the requirements for the authorship, and have read and approved the submitted manuscript. Ethical approval information: This research did not require patient consent or Institutional Review Board permission. American Journal of Therapeutics: May 2017 - Volume 24 - Issue 3 - p e347-e350 doi: 10.1097/MJT.0000000000000297 Buy Metrics Abstract Inflammation and insulin resistance are closely linked to each other. Inflammatory rheumatic diseases including rheumatoid arthritis (RA) are associated with increased insulin resistance and reduced insulin sensitivity by virtue of proinflammatory cytokines, mainly tumor necrosis factor alpha (TNF-α). TNF inhibitors have been shown to improve the insulin sensitivity and reduce the risk of incident diabetes in patients with RA. We hypothesize that TNF inhibitors may improve the glycemic control in patients with concomitant RA and diabetes mellitus. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.